Temodal is named as an intervention in 7 current clinical trials in our France, Germany, Italy, Switzerland, Canada, Australia, USA, Spain, Netherlands, Belgium, Sweden, Denmark, Austria and Taiwan registers. 5 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is CarThera (1). The most-studied condition is Glioblastoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Glioblastoma | 2 |
| Recurrent Glioblastoma | 1 |
| GBM | 1 |
| Glioma | 1 |
| CNS Tumor, Adult | 1 |
| CNS Tumor, Childhood | 1 |
| Glioma, Malignant | 1 |
| Recurrent Solid Tumor | 1 |
| Recurrent Ewing Sarcoma | 1 |
| Recurrent Hepatoblastoma | 1 |
| Recurrent Malignant Germ Cell Tumor | 1 |
| Malignant Neoplasm | 1 |
| Malignant Neoplasm of Brain | 1 |
| Glioblastoma Multiforme | 1 |
| Lead sponsor | Trials |
|---|---|
| CarThera | 1 |
| Global Coalition for Adaptive Research | 1 |
| Centre Leon Berard | 1 |
| Armando Santoro, MD | 1 |
| St. Jude Children's Research Hospital | 1 |
| Novelwise Pharmaceutical Corporation | 1 |
| University of Sydney | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our France, Germany, Italy, Switzerland, Canada, Australia, USA, Spain, Netherlands, Belgium, Sweden, Denmark, Austria and Taiwan registers name Temodal as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 3 with sites in France, 2 with sites in Germany, 1 with sites in Italy, 2 with sites in Switzerland, 2 with sites in Canada, 1 with sites in Australia, 1 with sites in USA, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Austria and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
CarThera (1), Global Coalition for Adaptive Research (1), Centre Leon Berard (1) and Armando Santoro, MD (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Temodal works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Temodal works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Temodal (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.